UACT

Quarantine day 6.

No lottery for life. beneluxa.org/news1

Novartis scandal : the product of a system encouraged by the lack of public policy, par @PeabodyJoshua via @MediapartBlogs blogs.mediapart.fr/edition/transp…

Drug companies have new ways to get paid for their expensive prescription drugs—some using patients’ digital medical records and other data to peg reimbursements to results wsj.com/articles/drugm… via @WSJ @ThiruGeneva So the future is even more expensive treatments?

What can we learn from the French system for controlling cost of meds? commonwealthfund.org/sites/default/…

Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer fiercepharma.com/pharma/roche-h…

Wrapping up 2019 – Noteworthy Medicines Law and Policy Events medicineslawandpolicy.org/2019/12/wrappi… via @MedsLawPolicy

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies fda.gov/news-events/pr…

KEI Request the NIH to Investigate Failure to Disclose Federal Funding in Opdivo and Keytruda Patents keionline.org/32076

@londeixp @MediapartBlogs @jamie_love @ThiruGeneva @londeixp The Observatory is asking the government, who ended up supporting the amendment, to issue a decree (disconnected from the social security bill), such as the one issued by Italy for instance.

@londeixp @MediapartBlogs The French constitutional council just censored the "transparency amendment" officially for a procedural matter.

L’amendement transparence censuré par le conseil constitutionnel, par @londeixp via @MediapartBlogs blogs.mediapart.fr/edition/transp…

The FDA’s Opaque Approach To Breast Density Communications disq.us/t/3kct0nz

How McKinsey infiltrated the world of global public health vox.com/science-and-he… via @voxdotcom

December 4 Public Lecture at Fordham with James Love t.e2ma.net/webview/4sauyb…

L'Assemblée Nationale adopte un amendement historique sur la transparence, par @londeixp via @MediapartBlogs blogs.mediapart.fr/edition/transp…

discussions on cell& gene therapies to treat cancer kicked down the road to 2021 & merged with rare and orphan diseases.WHO defers South Africa’s proposal on expanding access to cancer treatments including cell and gene therapies until 2021 keionline.org/32024

KEI and UACT Comments Regarding NIH Exclusive License on GPC3-Expressing Cancer Treatment keionline.org/31981

Italian Health Minister Moves To Replace Key Architect of WHA Resolution On Drug Price Transparency healthpolicy-watch.org/italian-health…

CRISPR Approach To Fighting Cancer Called 'Promising' In 1st Safety Test n.pr/2pwTsjo